CA3300454A1 — Use of rifaximin in subjects having diarrhea-predominant irritable bowel syndrome
Assigned to Salix Pharmaceuticals Inc · Expires 2026-03-02 · 0y expired
What this patent protects
The present invention relates to methods of predicting response to rifaximin treatment in subjects suffering from diarrhea-predominant Irritable Bowel Syndrome (d-IBS) based on assessment of age and / or length of duration of disease, where increased age or duration of disease in…
USPTO Abstract
The present invention relates to methods of predicting response to rifaximin treatment in subjects suffering from diarrhea-predominant Irritable Bowel Syndrome (d-IBS) based on assessment of age and / or length of duration of disease, where increased age or duration of disease increases the likelihood of positive treatment response. The present invention also relates to a dosage regimen for inducing a durable antibiotic response in selected patients.
Drugs covered by this patent
- Xifaxan (rifaximin) · Bausch Health
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.